The buprenorphine label says the benzodiazepine interaction is a reason to manage, not to refuse treatment
Suboxone's label: buprenorphine with benzodiazepines "increases the risk of adverse reactions including overdose, respiratory depression, and death," yet treatment "should not be categorically denied to patients taking these drugs."
Reasonable evidence with real limitations. how we score evidence
Caveat on this rating: The label balances two risks it does not quantify against each other. No figure for overdose deaths with buprenorphine plus benzodiazepines versus untreated opioid use disorder was read for this row.
Most interaction warnings tell a prescriber to avoid a combination. This one tells them not to let the interaction become a reason to withhold a life-saving drug.
Significant findings
The SUBOXONE sublingual film label (Indivior, February 2026), section 5.3: "Concomitant use of buprenorphine and benzodiazepines and/or other CNS depressants (e.g., alcohol, non-benzodiazepine sedative/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids [gabapentin or pregabalin], and other opioids) increases the risk of adverse reactions including overdose, respiratory depression, and death."
Then the sentence that sets this label apart: "Medication-assisted treatment of opioid use disorder, however, should not be categorically denied to patients taking these drugs. Prohibiting or creating barriers to treatment can pose an even greater risk of morbidity and mortality due to the opioid use disorder alone."
What the label asks for instead: "As a routine part of orientation to buprenorphine treatment, educate patients about the risks of concomitant use of benzodiazepines, sedatives, opioid analgesics, and alcohol. Develop strategies to manage use of prescribed or illicit benzodiazepines or other CNS depressants at initiation of buprenorphine treatment, or if it emerges as a concern during treatment. Adjustments to induction procedures and additional monitoring may be required."
Section 5.2 records where the deaths have come from: "Many, but not all, postmarketing reports regarding coma and death involved misuse by self-injection or were associated with the concomitant use of buprenorphine and benzodiazepines or other CNS depressants, including alcohol."
Worth asking
If you are on a benzodiazepine or an antipsychotic and are told you cannot start buprenorphine because of it, the label is on your side: the regulator's position is that the combination is a management problem, with the untreated opioid disorder as the larger risk. Ask what the management plan would be rather than accepting the refusal.
Source
SUBOXONE (buprenorphine and naloxone) sublingual film: FDA-approved prescribing information, Warnings and Precautions 5.2 and 5.3 — Indivior Inc.; US Food and Drug Administration (2026)
Regulator or national health body
How this was scored
- Study design
- Regulatory safety determination
- Funding
- Industry funded
- Published in
- Regulator or national health body
- Sample size
- not recorded
- Preregistered
- not recorded
- Conflicts disclosed
- not recorded
- Independent of proponent
- not recorded
- Retracted
- No
Read the full scoring rubric, including what it can't tell you.
Published September 21, 2026.
Questions
How strong is the evidence behind this?
veisund rates this source "moderate evidence". Reasonable evidence with real limitations. It scores 57 out of 100 on our published rubric. One caveat travels with that badge: The label balances two risks it does not quantify against each other. No figure for overdose deaths with buprenorphine plus benzodiazepines versus untreated opioid use disorder was read for this row. The score is calculated from recorded facts about the source — study design, funding, publication venue, sample size, preregistration — not typed in by an editor.
What is the source for this?
SUBOXONE (buprenorphine and naloxone) sublingual film: FDA-approved prescribing information, Warnings and Precautions 5.2 and 5.3 — Indivior Inc.; US Food and Drug Administration (2026). Published in: Regulator or national health body. The full source is linked on this page so you can read it yourself.
Who paid for this research, and does that matter?
Study design: Regulatory safety determination. Funding: Industry funded. Independence from the proponent is not recorded. Industry sponsorship is one of the most reliably measured biases in medicine, which is why funding carries real weight in the score rather than sitting in a footnote.
Is this medical advice?
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.